Related Experiment Videos
Betamimetics for suspected impaired fetal growth
1Special Department of Research, Development and Research Training in Human Reproduction, UNDP/UNFPA/WHO/World Bank, World Health Organisation, Geneva 27, Switzerland, CH-1211. gulmezoglum@who.ch
Background:
Betamimetic drugs may promote fetal growth by increasing the availability of nutrients and by decreasing vascular resistance. They may also induce adverse effects via their effects on carbohydrate metabolism.
Objectives:
The objective of this review was to assess the effects of betamimetic therapy for suspected impaired fetal growth on fetal growth and perinatal outcome.
Search Strategy:
We searched the Cochrane Pregnancy and Childbirth Group trials register and the Cochrane Controlled Trials Register. Date of the latest search: December 1999.
Selection Criteria:
Randomised trials of betamimetic therapy compared with no betamimetic therapy or placebo in women with suspected impaired fetal growth.
Data Collection And Analysis:
Eligibility and trial quality was assessed.
Main Results:
Two studies of 118 women were included. No differences were found between the betamimetic groups and the control groups for low birth weight (relative risk 1.17, 95% confidence interval 0.75 to 1.83), other anthropometric or neonatal morbidity and mortality measures.
Reviewer'S Conclusions:
There is not enough evidence to evaluate the use of betamimetics in promoting fetal growth. Larger studies are needed to investigate possible adverse effects of long-term betamimetic administration.